NASDAQ:QTNTQuotient Stock Price, Forecast & News

Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, QTNT shares have increased by 43.5% and is now trading at $6.66.
View which stocks have been most impacted by Coronavirus.

Quotient is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Quotient.

Quotient Ltd (NASDAQ:QTNT) released its earnings results on Monday, August, 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01.
View Quotient's earnings history.

Quotient updated its FY 2021 Pre-Market earnings guidance on Monday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $32-34 million, compared to the consensus revenue estimate of $36 million.

Media stories about QTNT stock have been trending negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Quotient earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future.
View the latest news about Quotient.

Some companies that are related to Quotient include Intellia Therapeutics (NTLA), Heska (HSKA), Myriad Genetics (MYGN), Lantheus (LNTH), Meridian Bioscience (VIVO), Vermillion (VRML), Oxford Immunotec Global (OXFD), Celldex Therapeutics (CLDX), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), ImmuCell (ICCC), Arca Biopharma (ABIO), Akers Biosciences (AKER) and Achieve Life Sciences (ACHV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Novavax (NVAX), Clovis Oncology (CLVS) and Micron Technology (MU).

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Quotient's stock is owned by a number of retail and institutional investors. Top institutional shareholders include TimesSquare Capital Management LLC (3.46%), Acuitas Investments LLC (0.31%), California Public Employees Retirement System (0.18%), Swiss National Bank (0.17%), Knott David M (0.16%) and Roubaix Capital LLC (0.14%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd.
View institutional ownership trends for Quotient.

QTNT stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, DAVENPORT & Co LLC, Swiss National Bank, and Arizona State Retirement System. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, Jeremy Stackawitz, and Roland Boyd.
View insider buying and selling activity for Quotient.

QTNT stock was bought by a variety of institutional investors in the last quarter, including Acuitas Investments LLC, Roubaix Capital LLC, California Public Employees Retirement System, New York State Common Retirement Fund, Aigen Investment Management LP, SG Americas Securities LLC, Knott David M, and State Board of Administration of Florida Retirement System. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von.
View insider buying and selling activity for Quotient.

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of QTNT stock can currently be purchased for approximately $6.66.

Quotient has a market capitalization of $537.08 million and generates $32.66 million in revenue each year. The company earns $-102,770,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

The official website for Quotient is www.quotientbd.com.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.